UNASSIGNED: In response to the 2009-2010 @entity683 A(H1N1)pdm09 pandemic, a mass vaccination programme with the AS03-adjuvanted @entity683 A(H1N1) vaccine Pandemrix was initiated in Sweden. Unexpectedly, there were a number of @entity2724 cases amongst vaccinated @entity1 and adolescents reported. In this review, we summarize the results of a joint cross-disciplinary national research effort to investigate the adverse reaction signal from the spontaneous reporting system and to better understand possible causative mechanisms. A three- to fourfold increased risk of @entity2724 in vaccinated @entity1 and adolescents was verified by epidemiological studies. Of importance, no risk increase was observed for the other neurological and @entity792 studied. Genetic studies confirmed the association with the allele @entity3098 *06:02, which is known to be related to @entity2724 . Furthermore, a number of studies using cellular and molecular experimental models investigated possible links between @entity683 vaccination and @entity2724 . Serum analysis, using a peptide microarray platform, showed that individuals who received Pandemrix exhibited a different epitope reactivity pattern to @entity689 and haemagglutinin, as compared to individuals who were infected with H1N1. @entity1 with @entity2724 were also found to have increased levels of @entity379 production in response to streptococcus-associated antigens. The chain of @entity1 -related events and the study results emerging over time were subjected to intense nationwide media attention. The importance of transparent communication and collaboration with @entity1 representatives to maintain public trust in vaccination programmes is also discussed in the review. Organizational challenges due to this unexpected event delayed the initiation of some of the research projects, still the main objectives of this joint, cross-disciplinary research effort were reached, and important insights were acquired for future, similar situations in which a fast and effective task force may be required to evaluate vaccination-related adverse events.

A coordinated cross-disciplinary research initiative to address an increased incidence of XXXX following the 2009-2010 Pandemrix vaccination programme in Sweden.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patient'] @entity689 :: ('4758', 'Gene') :: ['neuraminidase'] @entity3098 :: ('3119', 'Gene') :: ['HLA-DQB1'] @entity2724 :: ('MESH:D009290', 'Disease') :: ['narcolepsy', 'sporadic narcolepsy'] @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza'] @entity379 :: ('3458', 'Gene') :: ['interferon-gamma'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']
@entity2724 :: (MESH:D009290,Disease) :: ['narcolepsy']
